Silexion Therapeutics Corp

Contributing Author

Recent Articles by Silexion Therapeutics Corp

Dec-02	Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer SLXN GlobeNewswire
Nov-26	Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference SLXN GlobeNewswire
Nov-25	Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer SLXN GlobeNewswire
Nov-12	Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update SLXN GlobeNewswire
Sep-30	Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer SLXN GlobeNewswire
Sep-25	Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements SLXN GlobeNewswire
Sep-11	Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering SLXN GlobeNewswire
Sep-11	Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration SLXN GlobeNewswire
Sep-04	Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204 SLXN GlobeNewswire
Sep-02	Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference SLXN GlobeNewswire
Aug-12	Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update SLXN GlobeNewswire
Jul-31	Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds SLXN GlobeNewswire
Jul-31	Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation SLXN GlobeNewswire
Jul-16	Silexion Therapeutics Announces 1-for-15 Reverse Share Split SLXN GlobeNewswire
Jul-09	Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines SLXN GlobeNewswire
May-29	Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers SLXN GlobeNewswire
May-21	Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer SLXN GlobeNewswire
May-13	Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update SLXN GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.